» Articles » PMID: 21465263

Modifications of P53 and the DNA Damage Response in Cells Expressing Mutant Form of the Protein Huntingtin

Overview
Journal J Mol Neurosci
Date 2011 Apr 6
PMID 21465263
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) occurs through an expansion of the trinucleotide repeat in the HD gene resulting in the lengthening of the polyglutamine stretch within the N terminus of the protein, huntingtin (Htt). While the function of the protein is still being fully elucidated, we have shown that genomic DNA damage is associated with the expression of mutant Htt (mHtt) in a time-dependent fashion. With the accumulation of mHtt and its development into a micro-aggregated complex, the initiation of genomic damage engages a cellular stress signal that activates the DNA damage and stress response pathway. Here we explore the modifications and activation of p53 and keystone regulators of the cell stress response pathway using expression of a fragment of mHtt in HEK293T cells. We find an increase in phosphorylated p53 at serine 15 (S15), diminished acetylation at lysine 382 (K382), altered ubiquitination pattern, and oligomerization activity as a function of mHtt expression. As one might predict, upstream regulators of p53, such as CREB-binding protein/p300 and MDM2, are also seen to be affected by the expression of mHtt, albeit in different ways. These data suggest a possible relationship between p53 and the slow accumulation of DNA damage resulting from the expression of mHtt. The lack of a proper p53-mediated signaling cascade or its alteration in the presence of DNA damage may contribute to the slow progression of cellular dysfunction which is a hallmark of HD pathology.

Citing Articles

Therapeutic approaches targeting aging and cellular senescence in Huntington's disease.

Bhat A, Moglad E, Afzal M, Thapa R, Almalki W, Kazmi I CNS Neurosci Ther. 2024; 30(10):e70053.

PMID: 39428700 PMC: 11491556. DOI: 10.1111/cns.70053.


Mutant huntingtin protein induces MLH1 degradation, DNA hyperexcision, and cGAS-STING-dependent apoptosis.

Sun X, Liu L, Wu C, Li X, Guo J, Zhang J Proc Natl Acad Sci U S A. 2024; 121(13):e2313652121.

PMID: 38498709 PMC: 10990133. DOI: 10.1073/pnas.2313652121.


Tolfenamic acid inhibits ROS-generating oxidase Nox1-regulated p53 activity in intrastriatal injection of malonic acid rats.

Yang X, Zhang H, Qu T, Wang Y, Zhong Y, Yan Y J Physiol Sci. 2022; 72(1):15.

PMID: 35850611 PMC: 10717487. DOI: 10.1186/s12576-022-00842-4.


Mitochondrial Abnormalities and Synaptic Damage in Huntington's Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics.

Sawant N, Morton H, Kshirsagar S, Reddy A, Reddy P Mol Neurobiol. 2021; 58(12):6350-6377.

PMID: 34519969 DOI: 10.1007/s12035-021-02556-x.


How Do Post-Translational Modifications Influence the Pathomechanistic Landscape of Huntington's Disease? A Comprehensive Review.

Lontay B, Kiss A, Virag L, Tar K Int J Mol Sci. 2020; 21(12).

PMID: 32560122 PMC: 7349273. DOI: 10.3390/ijms21124282.


References
1.
Chehab N, Malikzay A, Stavridi E, Halazonetis T . Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci U S A. 1999; 96(24):13777-82. PMC: 24141. DOI: 10.1073/pnas.96.24.13777. View

2.
Harper P . Huntington's disease: a clinical, genetic and molecular model for polyglutamine repeat disorders. Philos Trans R Soc Lond B Biol Sci. 1999; 354(1386):957-61. PMC: 1692597. DOI: 10.1098/rstb.1999.0446. View

3.
Ahn J, Urist M, Prives C . The Chk2 protein kinase. DNA Repair (Amst). 2004; 3(8-9):1039-47. DOI: 10.1016/j.dnarep.2004.03.033. View

4.
Illuzzi J, Yerkes S, Parekh-Olmedo H, Kmiec E . DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates. J Neurosci Res. 2008; 87(3):733-47. DOI: 10.1002/jnr.21881. View

5.
Gu W, Roeder R . Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997; 90(4):595-606. DOI: 10.1016/s0092-8674(00)80521-8. View